BioLineRx (BLRX) FCF Margin (2024 - 2025)
BioLineRx's (BLRX) quarterly FCF Margin came in at 1649.48% in Q4 2025, down 157615.0% year-on-year from N/an in Q4 2024, and down 234.44% quarter-over-quarter from 493.21% in Q3 2025.
BioLineRx (BLRX) FCF Margin (2024 - 2025) Analysis & Trends
BioLineRx's FCF Margin history runs 2 years deep, the most recent figure standing at 1649.48% for Q4 2025.
- On a quarterly basis, FCF Margin fell 157615.0% year-over-year to 1649.48% in Q4 2025; TTM through Dec 2025 was 684.24%, a 53282.0% decrease from a year earlier, with the FY2025 full-year figure at 682.12%, down 53070.0% from the prior year.
- FCF Margin eased to 1649.48% in Q4 2025 per BLRX's latest filing, from 493.21% in the prior quarter.
- Across five years, FCF Margin topped out at 58.22% in Q2 2025 and bottomed at 1649.48% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | BioLineRx | 7.05 Bn | 7.06 Bn | 154,000.00 | -1,649.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,649.48% |
| Sep 30, 2025 | -493.21% |
| Jun 30, 2025 | -58.22% |
| Mar 31, 2025 | -1,016.08% |
| Dec 31, 2024 | -73.33% |
| Sep 30, 2024 | -198.77% |
| Jun 30, 2024 | -209.57% |
| Mar 31, 2024 | -205.35% |